Synopsis
Piramal Pharma’s management is optimistic that with revenue growth and margin expansion, it will be able to trim debt over the next five years. But the capital-intensive nature of its main contract manufacturing business scaling remains a challenge. Will Piramal Pharma be able to keep its investors happy?
In October, the demerged pharmaceuticals business of Piramal Enterprises — Piramal Pharma — got listed on the bourses. Two months on, the stock is down about 35% from its listing price of INR201.80 per share. There are several reasons that explain the stock’s performance. But largely, weak earnings in the first half of the current fiscal year, high debt and concerns over the company’s ability to improve margins and returns, given the capital
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
